Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Phone+1-617-5007867
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Aegerion Pharmaceuticals (NASDAQ:AEGR) Frequently Asked Questions
What is Aegerion Pharmaceuticals' stock symbol?
Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."
How were Aegerion Pharmaceuticals' earnings last quarter?
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) announced its earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $1.14. The biopharmaceutical company had revenue of $35.70 million for the quarter, compared to analyst estimates of $43 million. The company's revenue was down 39.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.55) EPS. View Aegerion Pharmaceuticals' Earnings History.
Has Aegerion Pharmaceuticals been receiving favorable news coverage?
News headlines about AEGR stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aegerion Pharmaceuticals earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
What other stocks do shareholders of Aegerion Pharmaceuticals own?
How do I buy shares of Aegerion Pharmaceuticals?
Shares of AEGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aegerion Pharmaceuticals' stock price today?
One share of AEGR stock can currently be purchased for approximately $1.97.
What is Aegerion Pharmaceuticals' official website?
How can I contact Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867.
MarketBeat Community Rating for Aegerion Pharmaceuticals (NASDAQ AEGR)
MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe AEGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
